On the 26th, Chordia Therapeutics <190A> announced that it will present research results related to its pipeline CDK12 inhibitor at the mini-symposium and poster session of the 47th Annual Meeting of the Molecular Biology Society of japan, held at Marinemesse Fukuoka.

The company is a research and development-oriented biotech venture specializing in cancer with clinical development products, working on multiple pipeline research and development including the CLK inhibitor rogocekib, the CDK12 inhibitor CTX-439, and the GCN2 inhibitor, etc.

The title of this presentation is "The Interaction of CDK12 and NXF1 Involved in DNA Damage Response." It reports that the CDK12 inhibitor targets RNA control stress through a newly identified mechanism of "RNA trucking" in addition to the known "transcription" and that "RNA trucking" may influence the extent of the anti-cancer effect of the CDK12 inhibitor. These findings are expected to lead to the identification of biomarkers that may predict the effectiveness of CDK12 inhibitors in the future.